according to the US FDA (https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products). "NV-387 ...
Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance ...
Getting good at LeetCode Java isn’t just about solving problems; it’s about having a good plan. You need to know where to start, what tools to use, and how to keep going when things get tough. This ...
Getting good at LeetCode Java can feel like a puzzle sometimes, right? You see all these problems, and you’re not sure where to even start. This guide is here to break down the common approaches and ...
SHELTON, CT, December 9, 2025 (EZ Newswire) -- NanoViricides, Inc. (NYSE American: NNVC, opens new tab) (the “Company”) today reported that it has received approval to start a Phase II clinical trial ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today reported that it has received approval to Start Phase II Clinical Trial of ...
Kiniksa Pharmaceuticals International said the Food and Drug Administration has granted orphan drug designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis. The ...
Los Angeles Housing Department launches its largest-ever affordable housing funding round, offering $387 million to developers starting Friday. The majority comes from Measure ULA’s “mansion tax” on ...
SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results